

Appendix 3 (as supplied by the authors): One-way sensitivity analyses and scenario analysis

Community follow-up cost ↓50%					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	588.0376		32.33195		-
S&T	254.9102	-333.127	32.48043	0.148478	Dominates
PT	176.5987	-78.3115	32.49497	0.014541	Dominates
Probability disease progression ↓50%					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	244.1808		32.45116		-
S&T	152.5585	-91.6223	32.52085	0.069686	Dominates
PT	97.8716	-54.6869	32.52767	0.006825	Dominates
Mean years to symptom onset doubled					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	590.0091		32.35042		-
S&T	255.1248	-334.884	32.49393	0.14351	Dominates
PT	176.3028	-78.8219	32.50798	0.014055	Dominates
Treatment failure rate doubled					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	586.6606		32.35014		-
S&T	310.8481	-275.813	32.47609	0.125958	Dominates
PT	237.8762	-72.9719	32.48843	0.012336	Dominates
Treatment adherence 50%					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	589.3176		32.3468		-
S&T	428.7695	-160.548	32.42936	0.08256	Dominates
PT	355.0411	-73.7284	32.43744	0.008086	Dominates
Empiric treatment adherence 15% less than with positive test					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	595.7445		32.33644		-
S&T	256.2383	-339.506	32.48723	0.15079	Dominates
PT	100.5738	-155.664	32.53031	0.043078	Dominates
ALL OF THE ABOVE TRUE					
	COST (\$)	Δ cost	QALYs	ΔQALYs	ICER
WW	241.6268		32.45834		-
S&T	232.0691	-9.55776	32.49207	0.033736	Dominates
PT	147.3703	-84.6988	32.5065	0.014431	Dominates